- Home
- OBE vs RIGL Comparison
OBE vs RIGL Comparison
Compare OBE & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OBE | RIGL |
|---|---|---|
| Founded | 1979 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.9M | 628.4M |
| IPO Year | 2005 | 2000 |
Fundamental Metrics
Financial Performance| Metric | OBE | RIGL |
|---|---|---|
| Price | $8.50 | $28.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $10.00 | ★ $43.20 |
| AVG Volume (30 Days) | ★ 533.5K | 332.3K |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 19.48 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | $66.81 |
| Revenue Next Year | $20.21 | N/A |
| P/E Ratio | ★ N/A | $1.48 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $3.88 | $15.50 |
| 52 Week High | $8.85 | $52.24 |
Technical Indicators
Market Signals| Indicator | OBE | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 64.74 | 26.00 |
| Support Level | $5.57 | $27.23 |
| Resistance Level | N/A | $31.26 |
| Average True Range (ATR) | 0.41 | 1.71 |
| MACD | 0.05 | -0.56 |
| Stochastic Oscillator | 79.31 | 6.52 |
Price Performance
Historical ComparisonAbout OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Sale of Oil.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.